{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:45:01Z","timestamp":1790819101713,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We aimed to develop and evaluate a population PK model of mycophenolic acid (MPA) in pediatric kidney transplant patients to aid MPA dose optimization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected from pediatric kidney transplant recipients from a Dutch academic hospital (Radboudumc, the Netherlands). Pharmacokinetic model-building and model-validation analyses were performed using NONMEM. Subsequently, we externally evaluated the final model using data from another academic hospital. The final model was used to develop an optimized dosing regimen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty pediatric patients were included of whom 266 measured MPA plasma concentrations, including 20 full pharmacokinetic (PK) curves and 24 limited sampling curves, were available. A two-compartment model with a transition compartment for Erlang-type absorption best described the data. The final population PK parameter estimates were K<jats:sub>tr<\/jats:sub> (1.48\u00a0h<jats:sup>\u22121<\/jats:sup>; 95% CI, 1.15\u20131.84), CL\/F (16.0 L h<jats:sup>\u22121<\/jats:sup>; 95% CI, 10.3\u201320.4), V<jats:sub>c<\/jats:sub>\/F (24.9 L; 95% CI, 93.0\u20136.71E25), V<jats:sub>p<\/jats:sub>\/F (1590 L; 95% CI, 651\u20132994), and Q\/F (36.2 L h<jats:sup>\u22121<\/jats:sup>; 95% CI, 9.63\u201374.7). The performance of the PK model in the external population was adequate. An optimized initial dose scheme based on bodyweight was developed. With the licensed initial dose, 35% of patients were predicted to achieve the target AUC, compared to 42% using the optimized scheme.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We have successfully developed a pharmacokinetic model for MPA in pediatric renal transplant patients. The optimized dosing regimen is expected to result in better target attainment early in treatment. It can be used in combination with model-informed follow-up dosing to further individualize the dose when PK samples become available.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03743-0","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T04:02:00Z","timestamp":1723867320000},"page":"1761-1771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Model-informed dose optimization of mycophenolic acid in pediatric kidney transplant patients"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0441-4514","authenticated-orcid":false,"given":"Astrid","family":"Heida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-9892","authenticated-orcid":false,"given":"Nynke G. L.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-969X","authenticated-orcid":false,"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8443","authenticated-orcid":false,"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huib","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-7056","authenticated-orcid":false,"given":"Ron J.","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-5264","authenticated-orcid":false,"given":"Elisabeth A. M.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"issue":"4","key":"3743_CR1","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/bcp.14590","volume":"87","author":"Y Rong","year":"2021","unstructured":"Rong Y, Jun H, Kiang TKL (2021) Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol 87(4):1730\u20131757","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3743_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/01.ftd.0000159784.25872.f6","volume":"27","author":"S Payen","year":"2005","unstructured":"Payen S, Zhang D, Maisin A, Popon M, Bensman A, Bouissou F et al (2005) Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 27(3):378\u2013388","journal-title":"Ther Drug Monit"},{"key":"3743_CR3","doi-asserted-by":"crossref","unstructured":"KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1\u2013155.","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"issue":"2","key":"3743_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F et al (2021) Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit 43(2):150\u2013200","journal-title":"Ther Drug Monit"},{"issue":"10","key":"3743_CR5","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","volume":"103","author":"DK Metz","year":"2019","unstructured":"Metz DK, Holford N, Kausman JY, Walker A, Cranswick N, Staatz CE et al (2019) Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation 103(10):2012\u20132030","journal-title":"Transplantation"},{"issue":"11","key":"3743_CR6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","volume":"7","author":"Y Le Meur","year":"2007","unstructured":"Le Meur Y, B\u00fcchler M, Thierry A, Caillard S, Villemain F, Lavaud S et al (2007) Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7(11):2496\u20132503","journal-title":"Am J Transplant"},{"issue":"2","key":"3743_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17425255.2021.1843633","volume":"17","author":"R Ehren","year":"2021","unstructured":"Ehren R, Schijvens AM, Hackl A, Schreuder MF, Weber LT (2021) Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opin Drug Metab Toxicol 17(2):201\u2013213","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"3743_CR8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1681\/ASN.V981511","volume":"9","author":"LT Weber","year":"1998","unstructured":"Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A et al (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 9(8):1511\u201320","journal-title":"J Am Soc Nephrol"},{"issue":"2S","key":"3743_CR9","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1097\/01.tp.0000186957.32801.c0","volume":"80","author":"R Ettenger","year":"2005","unstructured":"Ettenger R, Sarwal MM (2005) Mycophenolate mofetil in pediatric renal transplantation. Transplantation 80(2S):S201\u2013S210","journal-title":"Transplantation"},{"key":"3743_CR10","unstructured":"Roche. Summary of Product Characteristics (SPC) Cellcept: EMA; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cellcept-epar-product-information_en.pdf.\u00a0Accessed 25 Sept 2023"},{"key":"3743_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3743_CR12","doi-asserted-by":"publisher","first-page":"27966","DOI":"10.1038\/srep27966","volume":"6","author":"G Redlarski","year":"2016","unstructured":"Redlarski G, Palkowski A, Krawczuk M (2016) Body surface area formulae: an alarming ambiguity. Sci Rep 6:27966","journal-title":"Sci Rep"},{"issue":"6","key":"3743_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1208\/s12248-022-00769-z","volume":"24","author":"R Jelliffe","year":"2022","unstructured":"Jelliffe R, Liu J, Drusano GL, Martinez MN (2022) Individualized patient care through model-informed precision dosing: reflections on training future practitioners. AAPS J 24(6):117","journal-title":"AAPS J"},{"issue":"2","key":"3743_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/bcp.13119","volume":"83","author":"JF Standing","year":"2017","unstructured":"Standing JF (2017) Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol 83(2):247\u2013254","journal-title":"Br J Clin Pharmacol"},{"key":"3743_CR15","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303\u201311; discussion 12\u20133."},{"issue":"1","key":"3743_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00007691-200402000-00006","volume":"26","author":"A Rousseau","year":"2004","unstructured":"Rousseau A, L\u00e9ger F, Le Meur Y, Saint-Marcoux F, Paintaud G, Buchler M, Marquet P (2004) Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 26(1):23\u201330","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3743_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/BF02353481","volume":"24","author":"TC Krejcie","year":"1996","unstructured":"Krejcie TC, Jacquez JA, Avram MJ, Niemann CU, Shanks CA, Henthorn TK (1996) Use of parallel Erlang density functions to analyze first-pass pulmonary uptake of multiple indicators in dogs. J Pharmacokinet Biopharm 24(6):569\u2013588","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"3743_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","volume":"21","author":"BJ Anderson","year":"2011","unstructured":"Anderson BJ, Holford NHG (2011) Tips and traps analyzing pediatric PK data. Pediatr Anesth 21(3):222\u2013237","journal-title":"Pediatr Anesth"},{"issue":"6","key":"3743_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735\u2013750","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"3743_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Harling K, Karlsson MO (2016) Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn 43(6):583\u2013596","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"3743_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17\u201320","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3743_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569","journal-title":"AAPS J"},{"issue":"5","key":"3743_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40262-017-0593-6","volume":"57","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Ensom MHH (2018) Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet 57(5):547\u2013558","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3743_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM (2018) Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol 13(7):1085\u20131095","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3743_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, Sevestre M, Solodenko J, Weiss W et al (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401\u2013431","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3743_CR26","unstructured":"Bayer CropScience AG UHaSL. PopGen virtual population generator 2008. Available from: http:\/\/xnet.hsl.gov.uk\/popgen\/.\u00a0Accessed 25 July 2023"},{"issue":"12","key":"3743_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2165\/00002018-200528120-00007","volume":"28","author":"EN van Roon","year":"2005","unstructured":"van Roon EN, Flikweert S, le Comte M, Langendijk PNJ, Kwee-Zuiderwijk WJM, Smits P, Brouwers JRBJ (2005) Clinical relevance of drug-drug interactions. Drug Saf 28(12):1131\u20131139","journal-title":"Drug Saf"},{"issue":"11","key":"3743_CR28","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1177\/0091270009357429","volume":"50","author":"W Zhao","year":"2010","unstructured":"Zhao W, Fakhoury M, Desch\u00eanes G, Roussey G, Brochard K, Niaudet P et al (2010) Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 50(11):1280\u20131291","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3743_CR29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/bcp.12426","volume":"78","author":"M Dong","year":"2014","unstructured":"Dong M, Fukuda T, Cox S, de Vries MT, Hooper DK, Goebel J, Vinks AA (2014) Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol 78(5):1102\u20131112","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3743_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2010.10.017","volume":"63","author":"A Pr\u00e9maud","year":"2011","unstructured":"Pr\u00e9maud A, Weber LT, T\u00f6nshoff B, Armstrong VW, Oellerich M, Urien S et al (2011) Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res 63(3):216\u2013224","journal-title":"Pharmacol Res"},{"issue":"9","key":"3743_CR31","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40262-023-01280-0","volume":"62","author":"Y Rong","year":"2023","unstructured":"Rong Y, Wichart J, Hamiwka L, Kiang TKL (2023) Significant effects of renal function on mycophenolic acid total clearance in pediatric kidney transplant recipients with population pharmacokinetic modeling. Clin Pharmacokinet 62(9):1289\u20131303","journal-title":"Clin Pharmacokinet"},{"key":"3743_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113337","volume":"187","author":"A De Nicol\u00f2","year":"2020","unstructured":"De Nicol\u00f2 A, Ianniello A, Benagli C, Della Bruna R, Keller F, Antonucci M et al (2020) Lack of concordance between EMIT assay and LC-MS\/MS for therapeutic drug monitoring of mycophenolic acid: potential increased risk for graft rejection? J Pharm Biomed Anal 187:113337","journal-title":"J Pharm Biomed Anal"},{"issue":"10","key":"3743_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00467-008-0877-z","volume":"23","author":"S Irtan","year":"2008","unstructured":"Irtan S, Azougagh S, Monchaud C, Popon M, Baudouin V, Jacqz-Aigrain E (2008) Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatr Nephrol 23(10):1859\u20131865","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"3743_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/00007691-200412000-00005","volume":"26","author":"A Pr\u00e9maud","year":"2004","unstructured":"Pr\u00e9maud A, Rousseau A, Le Meur Y, Lach\u00e2tre G, Marquet P (2004) Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 26(6):609\u2013619","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3743_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/00007691-200112000-00013","volume":"23","author":"H Hosotsubo","year":"2001","unstructured":"Hosotsubo H, Takahara S, Imamura R, Kyakuno M, Tanaka T, Yazawa K et al (2001) Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit 23(6):669\u2013674","journal-title":"Ther Drug Monit"},{"issue":"4","key":"3743_CR36","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0041-1345(98)00201-2","volume":"30","author":"E Sch\u00fctz","year":"1998","unstructured":"Sch\u00fctz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, T\u00f6nshoff B et al (1998) Therapeutic drug monitoring of mycophenolic acid: comparison of hplc and immunoassay reveals new MPA metabolites. Transpl Proc 30(4):1185\u20131187","journal-title":"Transpl Proc"},{"issue":"3","key":"3743_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/clinchem\/48.3.517","volume":"48","author":"LT Weber","year":"2002","unstructured":"Weber LT, Shipkova M, Armstrong VW, Wagner N, Sch\u00fctz E, Mehls O et al (2002) Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 48(3):517\u2013525","journal-title":"Clin Chem"},{"issue":"3","key":"3743_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00007691-200406000-00011","volume":"26","author":"BA Atcheson","year":"2004","unstructured":"Atcheson BA, Taylor PJ, Kirkpatrick CM, Duffull SB, Mudge DW, Pillans PI et al (2004) Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 26(3):284\u2013286","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3743_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34(6):429\u2013455","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3743_CR40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/00007691-200110000-00003","volume":"23","author":"G Filler","year":"2001","unstructured":"Filler G, Lepage N, Delisle B, Mai I (2001) Effect of cyclosporine on mycophenolic acid area under the concentration\u2013time curve in pediatric kidney transplant recipients. Ther Drug Monit 23(5):514\u2013519","journal-title":"Ther Drug Monit"},{"issue":"10","key":"3743_CR41","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/00007890-199911270-00028","volume":"68","author":"PJ Gregoor","year":"1999","unstructured":"Gregoor PJ, de S\u00e9vaux RG, Hen\u00e9 RJ, Hesse CJ, Hilbrands LB, Vos P et al (1999) Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 68(10):1603\u20131606","journal-title":"Transplantation"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03743-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T06:03:26Z","timestamp":1728281006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03743-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3743"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03743-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ron Keizer is an employee and stockholder of InsightRX, a company developing clinical decision support software. The other authors have no competing interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}